Loading
Agilent Technologies, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Oct 2023.
Agilent Technologies, Inc.: what insiders have been doing
This page follows insider dealings at Agilent Technologies, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Santa Clara, United States. The group dates from 1999. Its latest reported headcount is 17,671 employees (2023). In the past year (18 October 2025 to 18 October 2026), 54 filings came from 22 insiders.
The flow runs one way only: 4 sales worth €1.0M, from 3 insiders, and no purchase. At €402k, the sale published on 1 December 2025 by Gonsalves Rodney is the largest of the period.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 54 filings, this issuer sits above that mark. Over the whole record (from 2016), the tally stands at 2 purchases and 51 sales. For the fiscal year to 31 October 2025, the annual 10-K puts revenue at 6.95 bn USD and net income at 1.30 bn USD, and the dividend at 0.99 USD per share.
Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
358
Thresholds
n/a
Buy Volume
€272
2 ops. · all time
Sell Volume
€55M
51 ops. · all time
Who traded when
BuySalePadraig Mcdonnell5 sales
Dolsten Mikael3 sales
Gonsalves Rodney2 sales
Daniel K. Podolsky1 sale
Judy L. Brown1 sale
Sue H. Rataj1 sale
Since the insiders bought
- +33.9%Entry US$110.90 · Close at T+365 US$148.48
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Agilent Technologies, Inc. Buy (bullish), based on 20 analysts. Average price target: US$180.30.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,900 of 24,158 companies
56.1
score / 100
Value38
Quality74
FCF yld2.4%
Earn yld2.7%
EV/EBITDA28.4x
ROE21%
Gross mgn52%
Net mgn19%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended October 2025 · cache
US$174.00
Analyst consensus
20 analystsBuy
US$155.00Target US$180.30(+4%)US$196.00
Income statement
RevenueUS$6.9B
Gross profitUS$3.6B52% margin
EBITDAUS$1.8B26% margin
Net incomeUS$1.3B19.5% margin
Valuation
PER (trailing)33.9x
PER (forward)25.8x
P/Book6.7x
Beta1.21
Balance sheet & cash
Market capUS$49.1B
Total debtUS$3.4B
Free Cash FlowUS$1.2B
Debt / Equity56%
Profitability & ownership
ROE21.0%
ROA8.6%
% insiders0.2%
% institutions95.4%
Last declaration on 10 September 2026
Declarations358 total
817 shares@ US$146.850.0002% mcap100.0% of flowCommon StockSEC:0001090872-26-000067:0
634 shares@ US$151.3750.0002% mcap4.7% of flowCommonSEC144:0001959173-26-006763
30 sharesCommon StockSEC:0001090872-26-000060:0
418 shares@ US$137.400.0001% mcap0.5% of flowCommon StockSEC:0001090872-26-000058:0
1,600 shares@ US$135.420.0005% mcap10.6% of flowCommon StockSEC:0001090872-26-000057:0
8,872 shares0Common StockSEC:0001090872-26-000046:0
153 shares@ US$113.98100.0% of flowCommon StockSEC:0001090872-26-000040:0
2,158 shares@ US$111.7511.1% of flowCommon StockSEC:0001090872-26-000039:0
2,158 shares@ US$111.7515.9% of flowCommon StockSEC:0001090872-26-000037:0
2,158 shares@ US$111.7513.7% of flowCommon StockSEC:0001090872-26-000036:0
2,158 shares@ US$111.7519.5% of flowCommon StockSEC:0001090872-26-000033:0
2,158 shares@ US$111.7511.9% of flowCommon StockSEC:0001090872-26-000027:0
2,158 shares@ US$111.7556.5% of flowCommon StockSEC:0001090872-26-000026:0
2,158 shares@ US$111.7519.5% of flowCommon StockSEC:0001090872-26-000024:0
2,158 shares@ US$111.7550.1% of flowCommon StockSEC:0001090872-26-000034:0
2,158 shares@ US$111.7515.8% of flowCommon StockSEC:0001090872-26-000029:0
2,158 shares@ US$111.756.8% of flowCommon StockSEC:0001090872-26-000028:0
279 shares@ US$121.380.3% of flowCommon StockSEC:0001090872-26-000021:0
124 shares@ US$121.382.3% of flowCommon StockSEC:0001090872-26-000020:0
89 shares@ US$121.381.2% of flowCommon StockSEC:0001090872-26-000022:0
2,600 shares@ US$149.81219.0% of flowCommon StockSEC:0001090872-25-000083:0
280 shares@ US$154.374.8% of flowCommon StockSEC:0001090872-25-000081:0
1,948 shares@ US$154.372.4% of flowCommon StockSEC:0001090872-25-000080:0
25 of 358 declarations
About Agilent Technologies, Inc.
Agilent Technologies, Inc. (NYSE: A) is a leading U.S. laboratory technology company listed on the New York Stock Exchange in the United States. From an international equity perspective, Agilent fits squarely within Health & Pharma, given its strong exposure to pharmaceutical, biopharmaceutical, diagnostics, academic, environmental, food, and industrial end markets. The company was incorporated in Delaware in May 1999 following the separation of Hewlett-Packard’s scientific instrumentation businesses, and it is managed from Santa Clara, California, while serving customers worldwide. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm?utm_source=openai))
Agilent’s business model centers on application-focused solutions across the laboratory workflow: instruments, software, services, and consumables. Following an organizational change announced in late 2024, the company now reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Life Sciences and Diagnostics Markets includes liquid chromatography, LC/MS-linked platforms, pathology, and companion diagnostics. Agilent CrossLab includes consumables, laboratory automation, software, informatics, and service-related offerings. Applied Markets includes gas chromatography, GC/MS, spectroscopy, remarketed instruments, and vacuum divisions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm?utm_source=openai))
Read moreShow less
Competitively, Agilent occupies a strong position in high-value analytical instrumentation, supported by a large installed base and a recurring revenue profile from consumables, service contracts, and software. Its differentiator is an integrated, workflow-oriented portfolio designed to improve laboratory productivity, compliance, and analytical throughput. That positioning places Agilent against other global instrumentation leaders, but with a meaningful specialization in analytical and clinical workflows. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm?utm_source=openai))
Key products and services include liquid and gas chromatography systems, LC/MS and GC/MS platforms, pathology solutions, companion diagnostics, laboratory consumables, and refurbishment services. Recent communications also highlight a stronger sustainability and circular-economy angle, with certified refurbishment centers, trade-in programs, and product launches aimed at improving instrument connectivity and lab productivity. ([agilent.com](https://www.agilent.com/about/newsroom/presrel/2025/27may-ca25017.html?utm_source=openai))
Geographically, Agilent has a genuinely global footprint, with operations and services across North America, Europe, and Asia-Pacific. Recent initiatives in Australia, India, Singapore, Malaysia, and South Korea underscore management’s push to deepen its presence in regional science hubs. On recent performance, the company reported first-quarter fiscal 2026 revenue of $1.80 billion, up 7.0% reported and 4.4% on a core basis, while continuing to expand its portfolio with new chromatography, pathology, and automation offerings. ([agilent.com](https://www.agilent.com/about/newsroom/presrel/2026/25feb-gp26003.html?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
